Canesten Thrush External Cream 2% w/w cream

Bayer plc🇬🇧 Electronic Medicines Compendium

Approval Date: N/A
Approval ID: a23f5309d30fd287
Company: Bayer plc
Type: Standard

Approval Details

Approval Id: a23f5309d30fd287
Drug Approval Emc Name: Canesten Thrush External Cream 2% w/w cream
Drug Name: Canesten Thrush External Cream 2% w/w cream
Company Name: Bayer plc
Company Address: 400 South Oak Way, Reading, Berkshire, RG2 6AD
Company Website: http://www.bayer.co.uk
Company Telephone: +44 (0)118 206 3000
Company Medical Info Email: medical.information@bayer.co.uk
Atc Code: D01AC01
Legal Category: Pharmacy
Authorisation Holder: Bayer plc 400 South Oak Way Reading RG2 6AD
Authorisation Number: PL 0010/0077
Authorisation Date: | | | | --- | --- | | Date of first authorisation: | 29 December 1980 | | Date of last renewal of authorisation: | 17 April 2002 |
Instruction Authorisation Holder: Bayer plc 400 South Oak Way Reading RG2 6AD
Instruction Authorisation Number: PL 0010/0077
Instruction Authorisation Date: | | | | --- | --- | | Date of first authorisation: | 29 December 1980 | | Date of last renewal of authorisation: | 17 April 2002 |
Instruction Composition: Clotrimazole 2% w/w. \*\*Excipients with known effect:\*\* Cetostearyl alcohol 100mg in each gram of cream Benzyl alcohol 20mg in each gram of cream For the full list of excipients, see section 6.1.
Instruction Dosage Form: Cream for topical use.
Instruction Clinical Particulars: 4.1 Therapeutic indications Canesten Thrush External Cream is recommended for the treatment of candidal vulvitis. It should be used as an adjunct to treatment of candidal vaginitis. It can also be used for treatment of the sexual partner's penis to prevent re-infection.4.2 Posology and method of administration Canesten Thrush External Cream should be applied to the vulva and surrounding area. It can also be applied to the sexual partner's penis to prevent re-infection. \*\*Adults\*\* The cream should be applied thinly two or three times daily and rubbed in gently. Treatment should be continued until symptoms of the infection disappear. However, if after concomitant treatment of the vaginitis, the symptoms do not improve within seven days, the patient should consult a doctor. If the cream is being used for treatment of the sexual partner's penis it should be applied two or three times daily for up to two weeks. \*\*Children\*\* There is no clinical experience in the use of Canesten Thrush External Cream in children.4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use Medical advice should be sought if this is the first time the patient has experienced symptoms of candidal vaginitis. Before using Canesten Thrush External Cream medical advice must be sought if any of the following are applicable: - more than two infections of candidal vaginitis in the last six months - previous history of a sexually transmitted disease or exposure to partner with sexually transmitted disease - pregnancy or suspected pregnancy - aged under 16 or over 60 years - known hypersensitivity to imidazoles or other vaginal antifungal products Canesten Thrush External Cream should not be used if the patient has any of the following symptoms whereupon medical advice should be sought: - irregular vaginal bleeding - abnormal vaginal bleeding or a blood-stained discharge - vulval or vaginal ulcers, blisters or sores - lower abdominal pain or dysuria - any adverse events such as redness, irritation or swelling associated with the treatment - fever or chills - nausea or vomiting - diarrhoea - foul smelling vaginal discharge This product contains cetostearyl alcohol, which may cause local skin reactions (e.g. contact dermatitis). The product also contains benzyl alcohol which may cause allergic reactions and mild local irritation.4.5 Interaction with other medicinal products and other forms of interaction Laboratory tests have suggested that, when used together, this product may cause damage to latex contraceptives. Consequently the effectiveness of such contraceptives may be reduced. Patients should be advised to use alternative precautions for at least five days after using this product.4.6 Fertility, pregnancy and lactation \*\*Pregnancy:\*\* There is a limited amount of data from the use of clotrimazole in pregnant women. Animal studies with clotrimazole have shown reproductive toxicity at high oral doses (see section 5.3). At the low systemic exposures of clotrimazole following topical treatment, harmful effects with respect to reproductive toxicity are not predicted. Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife \*\*Lactation:\*\* There are no data on the excretion of clotrimazole into human milk. However, systemic absorption is minimal after administration and is unlikely to lead to systemic effects. Clotrimazole may be used during breastfeeding. \*\*Fertility:\*\* No human studies of the effects of clotrimazole on fertility have been performed; however, animal studies have not demonstrated any effects of the drug on fertility.4.7 Effects on ability to drive and use machines Clotrimazole cream has no or negligible influence on the ability to drive or use machines.4.8 Undesirable effects Frequency not known. As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible Immune system disorder: anaphylactic reaction, angioedema, hypersensitivity Vascular disorder: syncope, hypotension Respiratory, thoracic and mediastinal disorders: dyspnea Skin and subcutaneous tissue disorders: blister, dermatitis contact, erythema, paraesthesia, skin exfoliation, pruritus, rash, urticaria, stinging skin/burning sensation skin. General disorders and administration site conditions: application site irritation, application site reaction, oedema, pain. \*\*Reporting of suspected adverse reactions\*\* Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose No risk of acute intoxication is seen as it is unlikely to occur following a single dermal application of an overdose (application over a large area under conditions favourable to absorption) or inadvertent oral ingestion. There is no specific antidote. However, in the event of accidental oral ingestion, routine measures such as gastric lavage should be performed only if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting). Gastric lavage should be carried out only if the airway can be protected adequately.
Instruction Pharmacology: 5.1 Pharmacodynamic properties \*\*Pharmacotherapeutic group:\*\* Antifungals for topical use – imidazole and triazole derivatives \*\*ATC Code:\*\* D01A C01 \*\*Mechanism of Action\*\* Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane. Clotrimazole has a broad antimycotic spectrum of action \*in vitro\* and \*in vivo\*, which includes dermatophytes, yeasts, moulds, etc. Under appropriate test conditions, the MIC values for these types of fungi are in the region of less than 0.062-8.0 µg/ml substrate. The mode of action of clotrimazole is primarily fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. \*In vitro\* activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive. In addition to its antimycotic action, clotrimazole also acts on gram-positive microorganisms (Streptococci / Staphylococci / Gardnerella vaginalis), and gram- negative microorganisms (Bacteroides). \*In vitro\* clotrimazole inhibits the multiplication of Corynebacteria and gram-positive cocci - with the exception of Enterococci - in concentrations of 0.5-10 µg/ml substrate. Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.5.2 Pharmacokinetic properties Pharmacokinetic investigations after dermal application have shown that clotrimazole is minimally absorbed from the intact or inflamed skin into the human blood circulation. The resulting peak serum concentrations of clotrimazole were below the detection limit of 0.001 mcg/ml, suggesting that clotrimazole applied topically is unlikely to lead to measurable systemic effects or side effects.5.3 Preclinical safety data Non-clinical data reveal no special hazard for humans based on studies of repeated dose toxicity, genotoxicity and carcinogenicity. Clotrimazole was not teratogenic in reproductive toxicity studies in mice, rats and rabbits. In rats high oral doses were associated with maternal toxicity, embryotoxicity, reduced fetal weights and decreased pup survival. In rats clotrimazole and/or its metabolites were secreted into milk at levels higher than in plasma by a factor of 10 to 20 at 4 hrs after administration, followed by a decline to a factor of 0.4 by 24 hrs.
Instruction Pharmaceutical Particulars: 6.1 List of excipients Sorbitan stearate Polysorbate 60 Cetyl palmitate Cetostearyl alcohol Octyldodecanol Benzyl alcohol Purified Water6.2 Incompatibilities Not applicable.6.3 Shelf life 10g Tube: 36 months. 20g Tube: 48 months6.4 Special precautions for storage 10g Tube: Do not store above 25°C. 20g Tube: This medicinal product does not require any special storage conditions.6.5 Nature and contents of container Aluminium tubes (10g and 20g) with internal lacquer coating, latex stopper and HDPE screw top.6.6 Special precautions for disposal and other handling No special requirements.
Instruction Content: ## Composition Clotrimazole 2% w/w. \*\*Excipients with known effect:\*\* Cetostearyl alcohol 100mg in each gram of cream Benzyl alcohol 20mg in each gram of cream For the full list of excipients, see section 6.1. ## Pharmaceutical Form Cream for topical use. ## Clinical Particulars 4.1 Therapeutic indications Canesten Thrush External Cream is recommended for the treatment of candidal vulvitis. It should be used as an adjunct to treatment of candidal vaginitis. It can also be used for treatment of the sexual partner's penis to prevent re-infection.4.2 Posology and method of administration Canesten Thrush External Cream should be applied to the vulva and surrounding area. It can also be applied to the sexual partner's penis to prevent re-infection. \*\*Adults\*\* The cream should be applied thinly two or three times daily and rubbed in gently. Treatment should be continued until symptoms of the infection disappear. However, if after concomitant treatment of the vaginitis, the symptoms do not improve within seven days, the patient should consult a doctor. If the cream is being used for treatment of the sexual partner's penis it should be applied two or three times daily for up to two weeks. \*\*Children\*\* There is no clinical experience in the use of Canesten Thrush External Cream in children.4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.4.4 Special warnings and precautions for use Medical advice should be sought if this is the first time the patient has experienced symptoms of candidal vaginitis. Before using Canesten Thrush External Cream medical advice must be sought if any of the following are applicable: - more than two infections of candidal vaginitis in the last six months - previous history of a sexually transmitted disease or exposure to partner with sexually transmitted disease - pregnancy or suspected pregnancy - aged under 16 or over 60 years - known hypersensitivity to imidazoles or other vaginal antifungal products Canesten Thrush External Cream should not be used if the patient has any of the following symptoms whereupon medical advice should be sought: - irregular vaginal bleeding - abnormal vaginal bleeding or a blood-stained discharge - vulval or vaginal ulcers, blisters or sores - lower abdominal pain or dysuria - any adverse events such as redness, irritation or swelling associated with the treatment - fever or chills - nausea or vomiting - diarrhoea - foul smelling vaginal discharge This product contains cetostearyl alcohol, which may cause local skin reactions (e.g. contact dermatitis). The product also contains benzyl alcohol which may cause allergic reactions and mild local irritation.4.5 Interaction with other medicinal products and other forms of interaction Laboratory tests have suggested that, when used together, this product may cause damage to latex contraceptives. Consequently the effectiveness of such contraceptives may be reduced. Patients should be advised to use alternative precautions for at least five days after using this product.4.6 Fertility, pregnancy and lactation \*\*Pregnancy:\*\* There is a limited amount of data from the use of clotrimazole in pregnant women. Animal studies with clotrimazole have shown reproductive toxicity at high oral doses (see section 5.3). At the low systemic exposures of clotrimazole following topical treatment, harmful effects with respect to reproductive toxicity are not predicted. Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife \*\*Lactation:\*\* There are no data on the excretion of clotrimazole into human milk. However, systemic absorption is minimal after administration and is unlikely to lead to systemic effects. Clotrimazole may be used during breastfeeding. \*\*Fertility:\*\* No human studies of the effects of clotrimazole on fertility have been performed; however, animal studies have not demonstrated any effects of the drug on fertility.4.7 Effects on ability to drive and use machines Clotrimazole cream has no or negligible influence on the ability to drive or use machines.4.8 Undesirable effects Frequency not known. As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible Immune system disorder: anaphylactic reaction, angioedema, hypersensitivity Vascular disorder: syncope, hypotension Respiratory, thoracic and mediastinal disorders: dyspnea Skin and subcutaneous tissue disorders: blister, dermatitis contact, erythema, paraesthesia, skin exfoliation, pruritus, rash, urticaria, stinging skin/burning sensation skin. General disorders and administration site conditions: application site irritation, application site reaction, oedema, pain. \*\*Reporting of suspected adverse reactions\*\* Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose No risk of acute intoxication is seen as it is unlikely to occur following a single dermal application of an overdose (application over a large area under conditions favourable to absorption) or inadvertent oral ingestion. There is no specific antidote. However, in the event of accidental oral ingestion, routine measures such as gastric lavage should be performed only if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting). Gastric lavage should be carried out only if the airway can be protected adequately. ## Pharmacological Properties 5.1 Pharmacodynamic properties \*\*Pharmacotherapeutic group:\*\* Antifungals for topical use – imidazole and triazole derivatives \*\*ATC Code:\*\* D01A C01 \*\*Mechanism of Action\*\* Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the fungal cytoplasmic membrane. Clotrimazole has a broad antimycotic spectrum of action \*in vitro\* and \*in vivo\*, which includes dermatophytes, yeasts, moulds, etc. Under appropriate test conditions, the MIC values for these types of fungi are in the region of less than 0.062-8.0 µg/ml substrate. The mode of action of clotrimazole is primarily fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. \*In vitro\* activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive. In addition to its antimycotic action, clotrimazole also acts on gram-positive microorganisms (Streptococci / Staphylococci / Gardnerella vaginalis), and gram- negative microorganisms (Bacteroides). \*In vitro\* clotrimazole inhibits the multiplication of Corynebacteria and gram-positive cocci - with the exception of Enterococci - in concentrations of 0.5-10 µg/ml substrate. Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.5.2 Pharmacokinetic properties Pharmacokinetic investigations after dermal application have shown that clotrimazole is minimally absorbed from the intact or inflamed skin into the human blood circulation. The resulting peak serum concentrations of clotrimazole were below the detection limit of 0.001 mcg/ml, suggesting that clotrimazole applied topically is unlikely to lead to measurable systemic effects or side effects.5.3 Preclinical safety data Non-clinical data reveal no special hazard for humans based on studies of repeated dose toxicity, genotoxicity and carcinogenicity. Clotrimazole was not teratogenic in reproductive toxicity studies in mice, rats and rabbits. In rats high oral doses were associated with maternal toxicity, embryotoxicity, reduced fetal weights and decreased pup survival. In rats clotrimazole and/or its metabolites were secreted into milk at levels higher than in plasma by a factor of 10 to 20 at 4 hrs after administration, followed by a decline to a factor of 0.4 by 24 hrs. ## Pharmaceutical Particulars 6.1 List of excipients Sorbitan stearate Polysorbate 60 Cetyl palmitate Cetostearyl alcohol Octyldodecanol Benzyl alcohol Purified Water6.2 Incompatibilities Not applicable.6.3 Shelf life 10g Tube: 36 months. 20g Tube: 48 months6.4 Special precautions for storage 10g Tube: Do not store above 25°C. 20g Tube: This medicinal product does not require any special storage conditions.6.5 Nature and contents of container Aluminium tubes (10g and 20g) with internal lacquer coating, latex stopper and HDPE screw top.6.6 Special precautions for disposal and other handling No special requirements.

Active Ingredients

Approved

Quick Info

Agency

UK EMC

Country

🇬🇧

Approval ID

a23f5309d30fd287

Type

Standard

Back to UK EMC Approvals